FUNDING
Coverage Timeline
newest firstAll Coverage
FUNDING$120M Series C
AusperBio Raises $120M for Hepatitis B Cure
AusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.
DEEP DIVE
FUNDING
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
FUNDING$180M Series B
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.